Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A2aR.KD.MSLN-CAR T cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous (typical For Car T Cell Therapies)[1]
01
Overview
A2aR.KD.MSLN-CAR T cells are genetically engineered chimeric antigen receptor (CAR) T cells designed to target and kill mesothelin-expressing tumor cells in solid tumors, with enhanced resistance to immunosuppression in the tumor microenvironment. These cells co-express an anti-mesothelin CAR and an shRNA that knocks down adenosine 2a receptor (A2aR), reducing the inhibitory effects mediated by adenosine signaling. The A2aR knockdown boosts proliferative, cytotoxic, and cytokine-producing capacities of the CAR T cells even under highly suppressive conditions, making this approach promising for solid tumor immunotherapy[1].
- Other names
- A2aR knockdown mesothelin CAR T cellsA-2aR knockdown mesothelin CAR T cellsA 2aR knockdown mesothelin CAR T cells
02
Targets
MesothelinADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on A2aR.KD.MSLN-CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A2aR.KD.MSLN-CAR T cells.